Association between cognition and color discrimination among Lebanese patients with schizophrenia.
Cognitive function
Color discrimination
Psychotic symptoms
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
12 09 2022
12 09 2022
Historique:
received:
02
05
2022
accepted:
06
09
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
15
9
2022
Statut:
epublish
Résumé
Patients with schizophrenia (SCZ) exhibit poorer color discrimination than normal individuals. Although retinal abnormalities, as well as cortical and subcortical alterations, found in patients with SCZ have been suggested to cause this poor color discrimination, the impact of cognitive impairment remains to be determined. Dopamine (DA) and glutamate (Glu), known to be disrupted in SCZ, are also suggested to play a role in color discrimination. Our objective was to investigate the contribution of cognitive impairment to color discrimination deficits in SCZ and to examine if these deficits are correlated to SCZ symptoms. This study includes 127 patients with SCZ between July and September 2021. The participants completed several questionnaires, specifically the Positive and Negative Syndrome Scale (PANSS), the Montreal Cognitive Assessment (MoCA) test, and the Farnsworth D-15 test, to assess the extent of SCZ symptoms, cognition, and color discrimination respectively. Higher cognition (Beta = - 0.279) was significantly associated with a lower total error score (TES). Moreover, a higher positive PANSS score (Beta = 0.217) was significantly associated with a higher TES. A multinomial regression analysis taking the type of color blindness as the dependent variable showed that female sex (ORa = 5.46) was significantly associated with a certain type of color blindness. Color discrimination deficits in patients with SCZ may be due to the effect of cognitive impairment and/or SCZ itself.
Sections du résumé
BACKGROUND
Patients with schizophrenia (SCZ) exhibit poorer color discrimination than normal individuals. Although retinal abnormalities, as well as cortical and subcortical alterations, found in patients with SCZ have been suggested to cause this poor color discrimination, the impact of cognitive impairment remains to be determined. Dopamine (DA) and glutamate (Glu), known to be disrupted in SCZ, are also suggested to play a role in color discrimination. Our objective was to investigate the contribution of cognitive impairment to color discrimination deficits in SCZ and to examine if these deficits are correlated to SCZ symptoms.
METHODS
This study includes 127 patients with SCZ between July and September 2021. The participants completed several questionnaires, specifically the Positive and Negative Syndrome Scale (PANSS), the Montreal Cognitive Assessment (MoCA) test, and the Farnsworth D-15 test, to assess the extent of SCZ symptoms, cognition, and color discrimination respectively.
RESULTS
Higher cognition (Beta = - 0.279) was significantly associated with a lower total error score (TES). Moreover, a higher positive PANSS score (Beta = 0.217) was significantly associated with a higher TES. A multinomial regression analysis taking the type of color blindness as the dependent variable showed that female sex (ORa = 5.46) was significantly associated with a certain type of color blindness.
CONCLUSION
Color discrimination deficits in patients with SCZ may be due to the effect of cognitive impairment and/or SCZ itself.
Identifiants
pubmed: 36096757
doi: 10.1186/s12888-022-04245-y
pii: 10.1186/s12888-022-04245-y
pmc: PMC9465930
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
606Informations de copyright
© 2022. The Author(s).
Références
Biol Psychiatry. 2004 Apr 15;55(8):834-41
pubmed: 15050865
Schizophr Res. 2020 May;219:84-94
pubmed: 31708400
J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):277-83
pubmed: 15377734
Schizophr Res. 2019 Feb;204:162-170
pubmed: 30201549
Schizophr Res. 2002 May 1;55(1-2):197-204
pubmed: 11955979
P T. 2014 Sep;39(9):638-45
pubmed: 25210417
Molecules. 2018 Aug 20;23(8):
pubmed: 30127324
Asian J Psychiatr. 2022 Apr;70:103029
pubmed: 35189473
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Schizophr Bull. 2009 Nov;35(6):1117-31
pubmed: 19793796
Genes Dis. 2015 Feb 25;2(2):211-218
pubmed: 30258865
Vision Res. 1997 Dec;37(24):3535-47
pubmed: 9425529
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):929-34
pubmed: 12369268
J Clin Psychiatry. 2005;66 Suppl 6:34-46
pubmed: 16107182
Curr Psychiatry Rep. 2015 May;17(5):28
pubmed: 25773224
Schizophr Res. 2010 Dec;124(1-3):134-41
pubmed: 20685082
Neuropsychology. 2005 Sep;19(5):649-656
pubmed: 16187883
Ann Neurol. 1982 May;11(5):478-83
pubmed: 6125124
Schizophr Res. 2003 Nov 15;64(2-3):91-101
pubmed: 14613674
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Am J Psychiatry. 1996 May;153(5):687-92
pubmed: 8615416
Schizophr Res Cogn. 2015 Jun;2(2):46-55
pubmed: 26345525
J Neurosci. 2006 Nov 1;26(44):11403-12
pubmed: 17079669
Biol Psychiatry. 2010 Feb 1;67(3):255-62
pubmed: 19897178
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
Vision Res. 2013 Aug 9;88:22-9
pubmed: 23810982
World Psychiatry. 2020 Feb;19(1):15-33
pubmed: 31922684
Int J Psychiatry Clin Pract. 2020 Jun;24(2):193-200
pubmed: 31916882
Psychiatr Danub. 2020 Spring;32(1):60-69
pubmed: 32303031